Iovance Biotherapeutics, Inc. (LON:0JDK)
 2.021
 -0.189 (-8.53%)
  At close: Oct 29, 2025
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $59.95M USD in the quarter ending June 30, 2025, with 92.73% growth. This brings the company's revenue in the last twelve months to $241.53M, up 636.99% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm) 
 $241.53M
Revenue Growth 
 +636.99%
P/S Ratio 
 3.04
Revenue / Employee 
 $288.22K
Employees 
 838
Market Cap 
536.75M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% | 
| Dec 31, 2023 | 1.19M | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | - | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Iovance Biotherapeutics News
- 13 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health - Nasdaq
- 20 days ago - Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play - Seeking Alpha
- 22 days ago - IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 5 weeks ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 2 months ago - Why Iovance Biotherapeutics Stock Got Mashed on Monday - The Motley Fool
- 2 months ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire